NCT01537744: A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma |
|
|
| Completed | 1 | 18 | US | oral 5-azacitidine in combination with romidepsin, 5-azacytidine, Vidaza, Istodax | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Celgene Corporation | Solid Tumors, Virally Mediated Cancers and Liposarcoma | 03/16 | 09/16 | | |
NCT02223052: Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies |
|
|
| Completed | 1 | 89 | US | CC-486, Oral Azacitdine, Vidaza, Azacitidine for Injection, AZA | Celgene | Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Osteosarcoma, Sarcoma, Thyroid Cancer, Genitourinary | 06/18 | 12/18 | | |
